Johann Bauersachs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6865090/publications.pdf

Version: 2024-02-01

353	42,091	4658 85	2828 191
papers	citations	h-index	g-index

371	371	371	33982
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
2	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
3	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2022, 43, 561-632.	2.2	2,169
4	MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456, 980-984.	27.8	2,111
5	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine, 2015, 373, 929-938.	27.0	1,827
6	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	2.2	1,396
7	MicroRNAs in the Human Heart. Circulation, 2007, 116, 258-267.	1.6	852
8	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
9	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	7.1	555
10	The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nature Communications, 2012, 3, 1078.	12.8	518
11	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	7.1	490
12	Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet, The, 2018, 392, 1047-1057.	13.7	467
13	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature, 2012, 485, 333-338.	27.8	450
14	Endothelial Nitric Oxide Synthase Uncoupling Impairs Endothelial Progenitor Cell Mobilization and Function in Diabetes. Diabetes, 2007, 56, 666-674.	0.6	371
15	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	1.7	370
16	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational	7.1	364
17	<scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020, MicroRNA-24 Regulates Vascularity After Myocardial Infarction. Circulation, 2011, 124, 720-730.	1.6	358
18	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2021, 60, 727-800.	1.4	344

#	Article	IF	Citations
19	MicroRNAs: novel regulators in cardiac development and disease. Cardiovascular Research, 2008, 79, 562-570.	3.8	310
20	Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1. Circulation Research, 2007, 100, 434-443.	4.5	269
21	Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure. Circulation, 2007, 115, 1754-1761.	1.6	262
22	Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovascular Research, 2008, 81, 474-481.	3.8	254
23	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. European Heart Journal, 2021, 42, 152-161.	2.2	249
24	Epidemiology, pathophysiology and contemporary management of cardiogenic shockÂâ€“Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
25	Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction. Circulation, 2001, 104, 982-985.	1.6	243
26	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal, 2017, 38, 2671-2679.	2.2	243
27	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	2.8	224
28	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	7.1	224
29	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
30	Suppression of Endothelial Progenitor Cells in Human Coronary Artery Disease by the Endogenous Nitric Oxide Synthase Inhibitor Asymmetric Dimethylarginine. Journal of the American College of Cardiology, 2005, 46, 1693-1701.	2.8	221
31	Gut Microbiotaâ€“Dependent Trimethylamine N -Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2225-2235.	2.4	219
32	Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3020-3030.	1.6	208
33	Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 263-275.	2.8	199
34	Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. Clinical Research in Cardiology, 2016, 105, 283-296.	3.3	197
35	Peripartum cardiomyopathy: current management and future perspectives. European Heart Journal, 2015, 36, 1090-1097.	2.2	196
36	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195

#	Article	IF	Citations
37	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. European Heart Journal, 2021, 42, 178-188.	2.2	190
38	Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction. Circulation, 2011, 123, 400-408.	1.6	189
39	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
40	Selfâ€care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	7.1	181
41	Short Communication: Asymmetric Dimethylarginine Impairs Angiogenic Progenitor Cell Function in Patients With Coronary Artery Disease Through a MicroRNA-21â€"Dependent Mechanism. Circulation Research, 2010, 107, 138-143.	4.5	177
42	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€"European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
43	Immune mechanisms in heart failure. European Journal of Heart Failure, 2017, 19, 1379-1389.	7.1	170
44	Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension, 2015, 65, 257-263.	2.7	169
45	Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. Nature Medicine, 2015, 21, 140-149.	30.7	168
46	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). European Journal of Heart Failure, 2017, 19, 1131-1141.	7.1	163
47	Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease. Frontiers in Immunology, 2018, 9, 706.	4.8	163
48	2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention, 2022, 17, e1126-e1196.	3.2	161
49	Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. Journal of Molecular and Cellular Cardiology, 2015, 87, 194-203.	1.9	160
50	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160
51	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	7.1	160
52	Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. Journal of the American College of Cardiology, 2003, 42, 1666-1673.	2.8	159
53	Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2015, 8, 1417-1426.	5.3	159
54	MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age, 2013, 35, 747-762.	3.0	150

#	Article	IF	Citations
55	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal, 2012, 33, 2782-2795.	2.2	148
56	Biogenesis and Regulation of Cardiovascular MicroRNAs. Circulation Research, 2011, 109, 334-347.	4.5	146
57	Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respiratory Medicine,the, 2018, 6, 368-378.	10.7	137
58	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal, 2016, 37, 2823-2829.	2.2	136
59	Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Research in Cardiology, 2019, 114, 2.	5.9	136
60	Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. European Heart Journal, 2022, 43, 2549-2561.	2.2	136
61	Small animal models of heart failure. Cardiovascular Research, 2019, 115, 1838-1849.	3.8	135
62	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	7.1	131
63	Heart failure drug treatment: the fantastic four. European Heart Journal, 2021, 42, 681-683.	2.2	131
64	The <scp>Heart Failure Association Atlas</scp>: <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. European Journal of Heart Failure, 2021, 23, 906-914.	7.1	130
65	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014, 35, 2295-2302.	2.2	128
66	Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. Journal of the American College of Cardiology, 2002, 39, 351-358.	2.8	127
67	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
68	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular functionâ€"value of the wearable cardioverter/defibrillator. European Journal of Heart Failure, 2014, 16, 1331-1336.	7.1	121
69	Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovascular Research, 2014, 103, 564-572.	3.8	121
70	Ablation of Mineralocorticoid Receptors in Myocytes But Not in Fibroblasts Preserves Cardiac Function. Hypertension, 2011, 57, 746-754.	2.7	118
71	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	7.1	118
72	Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. European Heart Journal, 2016, 38, ehw333.	2.2	115

#	Article	IF	Citations
73	Regulation of monocyte cell fate by blood vessels mediated by Notch signalling. Nature Communications, 2016, 7, 12597.	12.8	115
74	Immediate Mineralocorticoid Receptor Blockade Improves Myocardial Infarct Healing by Modulation of the Inflammatory Response. Hypertension, 2008, 51, 905-914.	2.7	113
75	Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction. Circulation, 2008, 118, 818-827.	1.6	111
76	Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. European Heart Journal, 2020, 41, 2983-2996.	2.2	108
77	Circulating cardiovascular <scp>microRNAs</scp> inÂcritically ill <scp>COVID</scp>â€19 patients. European Journal of Heart Failure, 2021, 23, 468-475.	7.1	107
78	Novel therapeutic approaches to post-infarction remodelling. Cardiovascular Research, 2012, 94, 293-303.	3.8	101
79	Longâ€term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2018, 20, 951-962.	7.1	101
80	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	7.1	101
81	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.2	101
82	Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. Journal of Clinical Investigation, 2011, 121, 461-462.	8.2	101
83	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	7.1	100
84	Mental disorders in adults with congenital heart disease: Unmet needs and impact on quality of life. Journal of Affective Disorders, 2016, 204, 180-186.	4.1	93
85	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92
86	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. European Heart Journal, 2017, 38, 2936-2943.	2.2	91
87	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure, 2017, 19, 1723-1728.	7.1	88
88	C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function. Circulation, 2019, 139, 1798-1812.	1.6	88
89	Low STAT3 expression sensitizes to toxic effects of Î²-adrenergic receptor stimulation in peripartum cardiomyopathy. European Heart Journal, 2017, 38, ehw086.	2.2	87
90	Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. International Journal of Cardiology, 2015, 196, 115-122.	1.7	83

#	Article	IF	Citations
91	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchâ€. European Heart Journal, 2017, 38, ehw597.	2.2	83
92	Blood vessel control of macrophage maturation promotes arteriogenesis in ischemia. Nature Communications, 2017, 8, 952.	12.8	83
93	Characterizing the Inflammatory Tissue Response to Acute Myocardial Infarction by Clinical Multimodality Noninvasive Imaging. Circulation: Cardiovascular Imaging, 2014, 7, 811-818.	2.6	82
94	Recommendations for extracorporeal cardiopulmonary resuscitation (eCPR): consensus statement of DGIIN, DGK, DGTHG, DGfK, DGNI, DGAI, DIVI and GRC. Clinical Research in Cardiology, 2019, 108, 455-464.	3.3	81
95	Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovascular Research, 2015, 106, 365-374.	3.8	80
96	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	2.2	79
97	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	2.2	78
98	C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and Failure. Circulation Research, 2017, 120, 66-77.	4.5	77
99	Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. Heart, 2016, 102, 390-396.	2.9	75
100	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
101	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clinical Research in Cardiology, 2020, 109, 1197-1222.	3.3	71
102	Mineralocorticoid Receptor Blockade Improves Vasomotor Dysfunction and Vascular Oxidative Stress Early After Myocardial Infarction. Hypertension, 2007, 50, 919-925.	2.7	70
103	Regulation of Myocardial Fibrosis by MicroRNAs. Journal of Cardiovascular Pharmacology, 2010, 56, 454-459.	1.9	69
104	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	7.1	69
105	Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillatorâ€"The PROLONG Study. Journal of the American Heart Association, 2017, 6, .	3.7	67
106	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clinical Research in Cardiology, 2017, 106, 582-589.	3.3	67
107	Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling: Presented in part at the 72nd Scientific Session of the American Heart Association, Atlanta, GA, USA, November 7-10, 1999, and published in abstract form (Circulation) Tj ETQq1 1 0.784314 rgBT /Ov	3.8	65
108	Differential Effects of Organic Nitrates on Endothelial Progenitor Cells Are Determined by Oxidative Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 748-754.	2.4	65

#	Article	IF	Citations
109	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
110	Early Escalation of Mechanical Circulatory Support Stabilizes and Potentially Rescues Patients in Refractory Cardiogenic Shock. Circulation: Heart Failure, 2020, 13, e005853.	3.9	63
111	Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Failure, 2015, 2, 139-149.	3.1	62
112	Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction. Circulation, 2015, 131, 1071-1081.	1.6	62
113	Growth Hormone Treatment Improves Markers of Systemic Nitric Oxide Bioavailability via Insulin-Like Growth Factor-I. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4172-4179.	3.6	60
114	Impact of COVID-19 outbreak on regional STEMI care in Germany. Clinical Research in Cardiology, 2020, 109, 1511-1521.	3.3	60
115	Clinical hemodynamic evaluation of patients implanted with a fully magnetically levitated left ventricular assist device (HeartMate 3). Journal of Heart and Lung Transplantation, 2017, 36, 28-35.	0.6	58
116	Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1934-1944.	6.4	58
117	Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thrombosis and Haemostasis, 2003, 89, 1024-1030.	3.4	57
118	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clinical Research in Cardiology, 2015, 104, 911-917.	3.3	55
119	The struggle towards a Universal Definition of Heart Failureâ€"how to proceed?. European Heart Journal, 2021, 42, 2331-2343.	2.2	55
120	Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries. International Journal of Cardiology, 2013, 167, 63-66.	1.7	52
121	Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. European Heart Journal, 2020, 41, 3564-3575.	2.2	52
122	Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. European Heart Journal, 2011, 32, 1275-1286.	2.2	51
123	Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Research in Cardiology, 2014, 109, 421.	5.9	51
124	Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Research in Cardiology, 2015, 110, 60.	5.9	51
125	Longâ€term followâ€up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular coâ€morbidities. European Journal of Heart Failure, 2019, 21, 1534-1542.	7.1	51
126	Rationale and design of the DIGITâ€HF trial (DIGitoxin to Improve ouTcomes in patients with advanced) Tj ETQq0 0 0 rgBT /Overlock 10 T Heart Failure, 2019, 21, 676-684.	7.1	51

#	Article	IF	Citations
127	Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy. Scientific Reports, 2019, 9, 20350.	3.3	50
128	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50
129	Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction. Journal of the American College of Cardiology, 2002, 40, 1695-1700.	2.8	49
130	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
131	Digoxinâ€“mortality: randomized vs. observational comparison in the DIG trial. European Heart Journal, 2019, 40, 3336-3341.	2.2	48
132	Inactivation of Sox9 in fibroblasts reduces cardiac fibrosis and inflammation. JCI Insight, 2019, 4, .	5.0	47
133	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation, 2016, 134, 1973-1990.	1.6	46
134	Acute coronary syndrome or Takotsubo cardiomyopathy: The suspect may not always be the culprit. International Journal of Cardiology, 2015, 187, 116-119.	1.7	44
135	First series of left ventricular assist device exchanges to HeartMate 3. European Journal of Cardio-thoracic Surgery, 2017, 51, 887-892.	1.4	44
136	Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. American Heart Journal, 2015, 170, 821-829.	2.7	43
137	Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 173-182.	1.0	43
138	The chemokine receptor <scp>CX</scp> ₃ <scp>CR</scp> 1 coordinates monocyte recruitment and endothelial regeneration after arterial injury. EMBO Molecular Medicine, 2018, 10, 151-159.	6.9	42
139	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	2.8	42
140	Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. European Heart Journal, 2017, 38, ehw577.	2.2	40
141	Sonic hedgehog-dependent activation of adventitial fibroblasts promotes neointima formation. Cardiovascular Research, 2017, 113, 1653-1663.	3.8	40
142	Simultaneous dual-isotope solid-state detector SPECT for improved tracking of white blood cells in suspected endocarditis. European Heart Journal, 2017, 38, ehw231.	2.2	39
143	Peripartum cardiomyopathy: from genetics to management. European Heart Journal, 2021, 42, 3094-3102.	2.2	39
144	One-year outcomes with the HeartMate 3 left ventricular assist device. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 662-669.	0.8	38

#	Article	IF	Citations
145	Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. Hypertension, 2019, 73, 102-111.	2.7	38
146	Modulation of platelet and monocyte function by the chemokine fractalkine (<scp>CX</scp>₃<scp>CL</scp>1) in cardiovascular disease. European Journal of Clinical Investigation, 2015, 45, 624-633.	3.4	37
147	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
148	The Treatment of Heart Failure with Reduced Ejection Fraction. Deutsches Ärzteblatt International, 2020, 117, 376-386.	0.9	37
149	Heart against veno-arterial ECMO: Competition visualized. International Journal of Cardiology, 2015, 187, 164-165.	1.7	36
150	Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome. Journal of Nuclear Medicine, 2022, 63, 1415-1423.	5.0	36
151	Exercise training improves vascular mitochondrial function. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H821-H829.	3.2	35
152	Mortality in Patients With Out-of-Hospital Cardiac Arrest Undergoing a Standardized Protocol Including Therapeutic Hypothermia and RoutineÂCoronary Angiography. JACC: Cardiovascular Interventions, 2018, 11, 1811-1820.	2.9	35
153	Heparan Sulfateâ€“Editing Extracellular Sulfatases Enhance VEGF Bioavailability for Ischemic Heart Repair. Circulation Research, 2019, 125, 787-801.	4.5	35
154	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. International Journal of Cardiology, 2016, 216, 165-167.	1.7	34
155	The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE, 2017, 12, e0184888.	2.5	34
156	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	2.4	34
157	Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis. Basic Research in Cardiology, 2021, 116, 26.	5.9	34
158	Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. Science, 2022, 376, 1343-1347.	12.6	34
159	Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS ONE, 2017, 12, e0183193.	2.5	33
160	Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region AfterÂAcute MyocardialÂInfarction. Journal of the American College of Cardiology, 2021, 77, 1835-1837.	2.8	33
161	Improvement of biological age by physical activity. International Journal of Cardiology, 2014, 176, 1187-1189.	1.7	32
162	Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H707-H712.	3.2	32

#	Article	IF	Citations
163	Regulator of G-Protein Signaling 5 Prevents Smooth Muscle Cell Proliferation and Attenuates Neointima Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 317-327.	2.4	32
164	EMC10 (Endoplasmic Reticulum Membrane Protein Complex Subunit 10) Is a Bone Marrowâ€“Derived Angiogenic Growth Factor Promoting Tissue Repair After Myocardial Infarction. Circulation, 2017, 136, 1809-1823.	1.6	32
165	The glucocorticoid receptor in monocyteâ€derived macrophages is critical for cardiac infarct repair and remodeling. FASEB Journal, 2017, 31, 5122-5132.	0.5	32
166	Cardiac iron concentration in relation to systemic iron status and disease severity in nonâ€ischaemic heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 2038-2046.	7.1	32
167	<scp>MiRNA</scp>â€181a is a novel regulator of aldosteroneâ€“mineralocorticoid receptorâ€mediated cardiac remodelling. European Journal of Heart Failure, 2020, 22, 1366-1377.	7.1	32
168	Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacological Research, 2010, 62, 432-438.	7.1	31
169	The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine. Journal of Nuclear Medicine, 2020, 61, 951-961.	5.0	31
170	Increased Cancer Prevalence in Peripartum Cardiomyopathy. JACC: CardioOncology, 2019, 1, 196-205.	4.0	30
171	Takotsubo syndrome: between evidence, myths, and misunderstandings. Herz, 2020, 45, 252-266.	1.1	30
172	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunctionâ€”a retrospective propensity score analysis. Leukemia, 2021, 35, 1301-1316.	7.2	30
173	Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure. Critical Care, 2020, 24, 701.	5.8	30
174	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clinical Research in Cardiology, 2019, 108, 290-297.	3.3	29
175	Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2813-2818.	2.4	28
176	First series of mechanical circulatory support in non-compaction cardiomyopathy: Is LVAD implantation a safe alternative?. International Journal of Cardiology, 2015, 197, 128-132.	1.7	28
177	Mortality in patients with cardiogenic shock treated with the Impella CP microaxial pump for isolated left ventricular failure. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 138-148.	1.0	28
178	Mechanical circulatory support for Takotsubo syndrome: a systematic review and meta-analysis. International Journal of Cardiology, 2020, 316, 31-39.	1.7	28
179	A novel openâ€source softwareâ€based highâ€precision workflow for target definition in cardiac radioablation. Journal of Cardiovascular Electrophysiology, 2020, 31, 2689-2695.	1.7	28
180	Assessment of myocardial function using MRI-based feature tracking in adults after atrial repair of transposition of the great arteries: Reference values and clinical utility. International Journal of Cardiology, 2016, 220, 246-250.	1.7	27

#	Article	IF	Citations
181	The role of l-arginine/l-homoarginine/nitric oxide pathway for aortic distensibility and intima-media thickness in stroke patients. Amino Acids, 2017, 49, 1111-1121.	2.7	27
182	Targeting of Extracellular RNA Reduces Edema Formation and Infarct Size and Improves Survival After Myocardial Infarction in Mice. Journal of the American Heart Association, 2017, 6, .	3.7	27
183	Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. Cardiovascular Drugs and Therapy, 2020, 34, 555-568.	2.6	27
184	Myeloid-Derived Growth Factor Protects Against Pressure Overloadâ€“Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca ²⁺ -ATPase Expression in Cardiomyocytes. Circulation, 2021, 144, 1227-1240.	1.6	27
185	Skeletal muscle derived Musclin protects the heart during pathological overload. Nature Communications, 2022, 13, 149.	12.8	27
186	Increased Cytochrome P4502E1 Expression and Altered Hydroxyeicosatetraenoic Acid Formation Mediate Diabetic Vascular Dysfunction. Diabetes, 2010, 59, 2001-2009.	0.6	26
187	Ventricular arrhythmias in patients with newly diagnosed nonischemic cardiomyopathy: Insights from the <scp>PROLONG</scp> study. Clinical Cardiology, 2017, 40, 586-590.	1.8	26
188	Diagnostic accuracy of cadmium-zinc-telluride-based myocardial perfusion SPECT: impact of attenuation correction using a co-registered external computed tomography. European Heart Journal Cardiovascular Imaging, 2016, 17, 1036-1043.	1.2	25
189	Initial experience with telemonitoring in left ventricular assist device patients. Journal of Thoracic Disease, 2019, 11, S853-S863.	1.4	25
190	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. European Heart Journal, 2021, 42, 657-670.	2.2	25
191	Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC). Korean Circulation Journal, 2017, 47, 543.	1.9	24
192	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	7.1	24
193	Induction of cardiomyocyte proliferation and angiogenesis protects neonatal mice from pressure overloadâ€“associated maladaptation. JCI Insight, 2019, 4, .	5.0	24
194	Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients. PLoS ONE, 2013, 8, e80454.	2.5	24
195	Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovascular Research, 2017, 113, cvw245.	3.8	23
196	Inflammatory Drivers of Cardiovascular Disease: Molecular Characterization of Senescent Coronary Vascular Smooth Muscle Cells. Frontiers in Physiology, 2020, 11, 520.	2.8	23
197	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <scp>FIDELIOâ€DKD</scp> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	7.1	23
198	Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction. Theranostics, 2021, 11, 7984-7994.	10.0	22

#	Article	IF	Citations
199	Expansion of CD10neg neutrophils and CD14+HLA-DRneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction. ELife, 2021, 10, .	6.0	22
200	Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. European Respiratory Journal, 2020, 56, 2000616.	6.7	22
201	Mineralocorticoid receptor in cardiovascular diseasesâ€"Clinical trials and mechanistic insights. British Journal of Pharmacology, 2022, 179, 3119-3134.	5.4	22
202	Immunity and inflammation: the neglected key players in congenital heart disease?. Heart Failure Reviews, 2022, 27, 1957-1971.	3.9	22
203	Blood-based microRNA profiling in patients with cardiac amyloidosis. PLoS ONE, 2018, 13, e0204235.	2.5	21
204	Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 2022, 19, 555-565.	13.7	21
205	Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances. European Journal of Clinical Investigation, 2012, 42, 1112-1120.	3.4	20
206	First-in-Man Fully Percutaneous Complete Bypass of Heart and Lung. JACC: Cardiovascular Interventions, 2017, 10, e231-e233.	2.9	20
207	Prediction of shortâ€•and longâ€term mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
208	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovascular Research, 2020, 116, 1875-1886.	3.8	20
209	Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. ESC Heart Failure, 2020, 7, 4394-4398.	3.1	20
210	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the <scp>ESC</scp> EORP PPCM Registry. European Journal of Heart Failure, 2021, 23, 2058-2069.	7.1	20
211	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. International Journal of Cardiology, 2021, 327, 138-145.	1.7	19
212	The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?. European Heart Journal, 2013, 34, 2426-2428.	2.2	18
213	Electric smog: telemetry interference between ICD and LVAD. Herzschrittmachertherapie Und Elektrophysiologie, 2017, 28, 257-259.	0.8	18
214	Bromocriptine for the Treatment of Peripartum Cardiomyopathy. Cardiac Failure Review, 2018, 4, 1.	3.0	18
215	Septal total atrial conduction time for prediction of atrial fibrillation in embolic stroke of unknown source: a pilot study. Clinical Research in Cardiology, 2020, 109, 205-214.	3.3	18
216	Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. ESC Heart Failure, 2020, 7, 512-522.	3.1	18

#	Article	IF	Citations
217	miRâ^'21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 1118.	2.4	18
218	Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. ESC Heart Failure, 2021, 8, 879-889.	3.1	18
219	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	1.7	18
220	Timely and individualized heart failure management: need for implementation into the new guidelines. Clinical Research in Cardiology, 2021, 110, 1150-1158.	3.3	18
221	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. Journal of the American Heart Association, 2021, 10, e014059.	3.7	18
222	NT-proBNP Indicates Left Ventricular Impairment and Adverse Clinical Outcome in Patients With Tetralogy of Fallot and Pulmonary Regurgitation. Canadian Journal of Cardiology, 2016, 32, 1247.e29-1247.e36.	1.7	17
223	<scp>TIP</scp> 30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation. EMBO Molecular Medicine, 2019, 11, e10018.	6.9	17
224	MAP-Kinase Activated Protein Kinase 2 Links Endothelial Activation and Monocyte/macrophage Recruitment in Arteriogenesis. PLoS ONE, 2015, 10, e0138542.	2.5	17
225	CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation. JACC: Cardiovascular Imaging, 2022, 15, 372-374.	5.3	17
226	Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications. Current Opinion in Pharmacology, 2013, 13, 280-286.	3.5	16
227	A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload. Cardiovascular Research, 2019, 115, 71-82.	3.8	16
228	Retinal myeloid cells regulate tip cell selection and vascular branching morphogenesis via Notch ligand Delta-like 1. Scientific Reports, 2019, 9, 9798.	3.3	16
229	Haemodynamic simulation and the effect of early left ventricular unloading in preâ€shock acute coronary syndrome. ESC Heart Failure, 2019, 6, 457-463.	3.1	16
230	Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone. ESC Heart Failure, 2015, 2, 150-158.	3.1	15
231	Pentaerythritol Tetranitrate Targeting Myocardial Reactive Oxygen Species Production Improves Left Ventricular Remodeling and Function in Rats With Ischemic Heart Failure. Hypertension, 2015, 66, 978-987.	2.7	15
232	Systemic application of sirolimus prevents neointima formation not via a direct anti-proliferative effect but via its anti-inflammatory properties. International Journal of Cardiology, 2017, 238, 79-91.	1.7	15
233	Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI. International Journal of Cardiology, 2017, 232, 155-159.	1.7	15
234	BET bromodomain-containing epigenetic reader proteins regulate vascular smooth muscle cell proliferation and neointima formation. Cardiovascular Research, 2021, 117, 850-862.	3.8	15

#	Article	IF	Citations
235	Five-year outcomes of patients supported with HeartMate 3: a single-centre experience. European Journal of Cardio-thoracic Surgery, 2021, 59, 1155-1163.	1.4	15
236	Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney International Supplements, 2022, 12, 19-26.	14.2	15
237	Organic Nitrates Differentially Modulate Circulating Endothelial Progenitor Cells and Endothelial Function in Patients with Symptomatic Coronary Artery Disease. Antioxidants and Redox Signaling, 2011, 15, 925-931.	5.4	14
238	Poor Outcomes in Poor Patients?. JAMA Cardiology, 2017, 2, 1261.	6.1	14
239	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women. European Journal of Preventive Cardiology, 2019, 26, 1903-1906.	1.8	14
240	Echocardiographic Changes in Patients Implanted With a Fully Magnetically Levitated Left Ventricular Assist Device (Heartmate 3). Journal of Cardiac Failure, 2019, 25, 36-43.	1.7	14
241	Extracorporeal Membrane Oxygenation for Severe ARDS Due to Immune Diffuse Alveolar Hemorrhage. Chest, 2020, 157, 744-747.	0.8	14
242	Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD). Clinical Research in Cardiology, 2020, 109, 1035-1047.	3.3	14
243	Early use of hemoadsorption in patients after out-of hospital cardiac arrest â€“ a matched pair analysis. PLoS ONE, 2020, 15, e0241709.	2.5	14
244	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	2.2	14
245	miR-21: a central regulator of fibrosis not only in the broken heart: EXPERT'S PERSPECTIVE. Cardiovascular Research, 2012, 96, 227-229.	3.8	13
246	Plasma Concentrations of Myeloid-Derived Growth Factor in Healthy Individuals and Patients with Acute Myocardial Infarction as Assessed by Multiple Reaction Monitoring-Mass Spectrometry. Analytical Chemistry, 2019, 91, 1302-1308.	6.5	13
247	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 57-68.	3.0	13
248	Diverging Trends in Age at First Myocardial Infarction: Evidence from Two German Population-Based Studies. Scientific Reports, 2020, 10, 9610.	3.3	13
249	Neuromarkers and neurological outcome in out-of-hospital cardiac arrest patients treated with therapeutic hypothermiaâ€“experience from the HAnnover COoling REgistry (HACORE). PLoS ONE, 2021, 16, e0245210.	2.5	13
250	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. European Heart Journal, 2022, 43, 367-376.	2.2	13
251	The Three-Decade Long Journey in Heart Failure Drug Development. Handbook of Experimental Pharmacology, 2016, 243, 1-14.	1.8	12
252	Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury. Cardiovascular Research, 2019, 115, 1804-1810.	3.8	12

#	Article	IF	Citations
253	Lateral Thoracotomy for Ventricular Assist Device Implantation: A Meta-Analysis of Literature. ASAIO Journal, 2021, 67, 845-855.	1.6	12
254	Extended followâ€up after wearable cardioverterâ€defibrillator period: the PROLONGâ€I study. ESC Heart Failure, 2021, 8, 5142-5148.	3.1	12
255	Intermediate CD14++CD16+ monocytes decline after transcatheter aortic valve replacement and correlate with functional capacity and left ventricular systolic function. PLoS ONE, 2017, 12, e0183670.	2.5	12
256	Use of extracorporeal membrane oxygenation for eCPR in the emergency room in patients with refractory out-of-hospital cardiac arrest. PLoS ONE, 2020, 15, e0239777.	2.5	12
257	Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity. Scientific Reports, 2018, 8, 11227.	3.3	11
258	Echocardiography and biomarkers for the diagnosis ofÂcardiotoxicity. Herz, 2020, 45, 637-644.	1.1	11
259	Genetic ablation of fibroblast activation protein alpha attenuates left ventricular dilation after myocardial infarction. PLoS ONE, 2021, 16, e0248196.	2.5	11
260	Hospitalizations for heart failure: still major differences between East and West Germany 30Âyears after reunification. ESC Heart Failure, 2021, 8, 2546-2555.	3.1	11
261	Computed-Tomography as First-line Diagnostic Procedure in Patients With Out-of-Hospital Cardiac Arrest. Frontiers in Cardiovascular Medicine, 2022, 9, 799446.	2.4	11
262	Spike rate of multi-unit muscle sympathetic nerve fibers after catheter-based renal nerve ablation. Journal of the American Society of Hypertension, 2015, 9, 794-801.	2.3	10
263	New drugs: big changes in conservative heart failure therapy?. European Journal of Cardio-thoracic Surgery, 2019, 55, i3-i10.	1.4	10
264	Depression Associated with Reduced Heart Rate Variability Predicts Outcome in Adult Congenital Heart Disease. Journal of Clinical Medicine, 2021, 10, 1554.	2.4	10
265	Anticoagulants for stroke prevention in heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2022, 111, 1-13.	3.3	10
266	Factors That Influence Adherence to Medication in Adults With Congenital Heart Disease (ACHD). Frontiers in Psychiatry, 2021, 12, 788013.	2.6	10
267	Therapeutic Hypothermia Following Cardiac Arrest After the TTM2 trial â€“ More Questions Raised Than Answered. Current Problems in Cardiology, 2023, 48, 101046.	2.4	10
268	Cardiomyocyte Mineralocorticoid Receptor Function Post Myocardial Infarction. Trends in Cardiovascular Medicine, 2011, 21, 42-47.	4.9	9
269	Multidrug resistance associated protein-1 (MRP1) deficiency attenuates endothelial dysfunction in diabetes. Journal of Diabetes and Its Complications, 2016, 30, 623-627.	2.3	9
270	Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clinical Research in Cardiology, 2017, 106, 722-733.	3.3	9

#	Article	IF	Citations
271	Prevalence of Child Maltreatment in Adults With Congenital Heart Disease and Its Relationship With Psychological Well-Being, Health Behavior, and Current Cardiac Function. Frontiers in Psychiatry, 2021, 12, 686169.	2.6	9
272	Impella Mechanical Circulatory Support for Takotsubo Syndrome With Shock: A Retrospective Multicenter Analysis. Cardiovascular Revascularization Medicine, 2022, 40, 113-119.	0.8	9
273	Takotsubo cardiomyopathy: Completely simple but not so easy. International Journal of Cardiology, 2015, 197, 257-259.	1.7	8
274	Normal endothelial but impaired arterial development in MAP-Kinase activated protein kinase 2 (MK2) deficient mice. Vascular Cell, 2016, 8, 4.	0.2	8
275	A mechanistic model for atherosclerosis and its application to the cohort of Mayak workers. PLoS ONE, 2017, 12, e0175386.	2.5	8
276	Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis. Vascular Pharmacology, 2018, 107, 20-26.	2.1	8
277	Evaluation of Myocardial Gene Expression Profiling for Superior Diagnosis of Idiopathic Giant-Cell Myocarditis and Clinical Feasibility in a Large Cohort of Patients with Acute Cardiac Decompensation. Journal of Clinical Medicine, 2020, 9, 2689.	2.4	8
278	Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy. Scientific Reports, 2021, 11, 1755.	3.3	8
279	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	3.1	8
280	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	3.3	8
281	Artificial Intelligence Identifies an Urgent Need for Peripheral Vascular Intervention by Multiplexing Standard Clinical Parameters. Biomedicines, 2021, 9, 1456.	3.2	8
282	Analysis of myocardial cellular gene expression during pressure overload reveals matrix based functional intercellular communication. IScience, 2022, 25, 103965.	4.1	8
283	Anti-androgenic therapy with finasteride in patients with chronic heart failure - a retrospective propensity score based analysis. Scientific Reports, 2019, 9, 10139.	3.3	7
284	Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to Pneumocystis pneumonia. European Respiratory Journal, 2019, 54, 1900410.	6.7	7
285	Prediction of heart failure and death in an adult population of Fontan patients. Cardiology in the Young, 2019, 29, 602-609.	0.8	7
286	Heart rate control in heart failure with reduced ejection fraction: the bright and the dark side of the moon. European Journal of Heart Failure, 2020, 22, 539-542.	7.1	7
287	Mechanical circulatory support in refractory cardiogenic shock due to influenza virus-related myocarditis. European Respiratory Journal, 2020, 56, 2000925.	6.7	7
288	Cardiooncologyâ€"dealing with modern drug treatment, long-term complications, and cancer survivorship. Clinical and Experimental Metastasis, 2021, 38, 361-371.	3.3	7

#	Article	IF	Citations
289	Targeting the aldosterone pathway in cardiovascular disease. Fundamental and Clinical Pharmacology, 2012, 26, 135-145.	1.9	6
290	Mid-term results of interventional closure of patent foramen ovale with the Occlutech FigullaÂ® Flex II Occluder. BMC Cardiovascular Disorders, 2016, 16, 217.	1.7	6
291	Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. Clinical Research in Cardiology, 2021, 110, 759-774.	3.3	6
292	Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverterâ€“Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction. Sensors, 2021, 21, 7798.	3.8	6
293	Modeling Cardiac Fibrosis in Mice: (Myo)Fibroblast Phenotype After Ischemia. Methods in Molecular Biology, 2017, 1627, 123-137.	0.9	5
294	Devil in Disguise. Circulation: Heart Failure, 2018, 11, e004620.	3.9	5
295	Increased epicardial adipose tissue in young adults with congenital heart disease comorbid with major depressive disorder. Journal of Affective Disorders, 2019, 257, 678-683.	4.1	5
296	Effects of six month personalized endurance training on work ability in middle-aged sedentary women: a secondary analysis of a randomized controlled trial. Journal of Occupational Medicine and Toxicology, 2020, 15, 8.	2.2	5
297	Perhexiline treatment improves toxic effects of Î²â€adrenergic receptor stimulation in experimental peripartum cardiomyopathy. ESC Heart Failure, 2021, 8, 3375-3381.	3.1	5
298	Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. Clinical Research in Cardiology, 2022, 111, 233-236.	3.3	5
299	Mineralocorticoid Receptor-Dependent Adverse Remodeling After Myocardial Infarction Mediated by uNGALant Activation of NFÎºB. Hypertension, 2017, 70, 1080-1081.	2.7	4
300	The European Society of Cardiology Heart Failure Association Study Group on Peripartum CardiomyopathyÂâ€“Âwhat has been achieved in 10â€‰years. European Journal of Heart Failure, 2020, 22, 1060-1064.	7.1	4
301	Unloading in Refractory Cardiogenic Shock After Out-Of-Hospital Cardiac Arrest Due to Acute Myocardial Infarctionâ€”A Propensity Score-Matched Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 704312.	2.4	4
302	Standardized secondary prevention in patients with ST-elevation myocardial infarction. European Journal of Preventive Cardiology, 2020, , .	1.8	4
303	Additive Impact of Interleukin 6 and Neuron Specific Enolase for Prognosis in Patients With Out-of-Hospital Cardiac Arrest â€“ Experience From the HAnnover COoling REgistry. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	4
304	Clinical care for patients with recurrent myocardial ischemia in Germanyâ€”the VOICES trial. Journal of Thoracic Disease, 2018, 10, S1777-S1784.	1.4	3
305	Advanced Preconditioning: Impella 5.5 Support for Decompensated Heart Failure Before Left Ventricular Assist Device Surgery. Cardiovascular Revascularization Medicine, 2021, 28, 189-192.	0.8	3
306	ECG and arrhythmias in peripartum cardiomyopathy. Herzschrittmachertherapie Und Elektrophysiologie, 2021, 32, 207-213.	0.8	3

#	Article	IF	Citations
307	Circulating microRNAs in Symptomatic and Asymptomatic Carotid Stenosis. Frontiers in Neurology, 2021, 12, 755827.	2.4	3
308	Echocardiographic Parameters to Predict Atrial Fibrillation in Clinical Routineâ€"The EAHsy-AF Risk Score. Frontiers in Cardiovascular Medicine, 2022, 9, 851474.	2.4	3
309	Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiologyâ€"A PROLONG-II Substudy. Sensors, 2022, 22, 2037.	3.8	3
310	Single coronary artery anomaly with interarterial left main: caught inbetween. European Heart Journal, 2015, 36, 762-762.	2.2	2
311	Leukocytoclastic vasculitis associated with endocarditis in a patient with transposition of the great arteries and mechanical valve replacement. Cardiovascular Pathology, 2017, 27, 68-70.	1.6	2
312	Reply to â€˜Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a nationwide Danish cohortâ€™. European Heart Journal, 2018, 39, 3478-3478.	2.2	2
313	Maintenance Immunosuppression Is Associated With Better Outcome in the 2017/2018 Influenza Epidemic. Open Forum Infectious Diseases, 2019, 6, ofz381.	0.9	2
314	Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. New England Journal of Medicine, 2019, 381, 2373-2374.	27.0	2
315	Safe Exchange of a Transfemoral Impella Pump. Cardiovascular Revascularization Medicine, 2019, 20, 827-828.	0.8	2
316	Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy. Clinical Research in Cardiology, 2020, 109, 539-548.	3.3	2
317	The Value of an Immediate Invasive Strategy in Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2020, 13, 2303-2304.	2.9	2
318	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. Europace, 2023, 25, .	1.7	2
319	A mouse model of cardiogenic shock. Cardiovascular Research, 2021, 117, 2414-2415.	3.8	2
320	P2Y12 inhibition in acute coronary syndromes treated with percutaneous intervention â€“ Understanding the debate on Prasugrel or Ticagrelor. , 2021, , 108029.		2
321	Survey of clinical practice pattern in Germanyâ€™s certified chest pain units. Herz, 2021, , 1.	1.1	2
322	Novel selfâ€expanding <scp>ALLEGRA</scp> transcatheter aortic valve for native aortic stenosis and degenerated bioprosthesis. Catheterization and Cardiovascular Interventions, 2022, 99, 1234-1242.	1.7	2
323	Thromboembolic characteristics and role of anticoagulation in long-standing Fontan circulation. International Journal of Cardiology Congenital Heart Disease, 2022, 7, 100328.	0.4	2
324	Right Ventricular Function Improves Early After Percutaneous Mitral Valve Repair in Patients Suffering From Severe Mitral Regurgitation. Frontiers in Cardiovascular Medicine, 2022, 9, 830944.	2.4	2

#	Article	IF	Citations
325	Impact of COVID-19 on Medical Supply in Adults With Congenital Heart Disease. Frontiers in Psychiatry, 2022, 13, 812611.	2.6	2
326	Impact of fasting on stress systems and depressive symptoms in patients with major depressive disorder: a cross-sectional study. Scientific Reports, 2022, 12, 7642.	3.3	2
327	Takotsubo cardiomyopathy â€" Everything's illuminated?. International Journal of Cardiology, 2015, 196, 36-37.	1.7	1
328	Consequences of ventricular tachyarrhythmia in patients with a left ventricular assist device: Live recording in the ICU. Acute Cardiac Care, 2015, 17, 36-37.	0.2	1
329	Mineralocorticoid Receptor Antagonists in the Treatment of Coronary Artery Disease, Myocardial Infarction and Heart Failure. , 0, , .		1
330	Inter- and Intracellular Mechanisms of Cardiac Remodeling, Hypertrophy and Dysfunction. Cardiovascular Medicine, 2019, , 39-56.	0.0	1
331	Breastfeeding in Patients With HeartÂFailure. JACC Basic To Translational Science, 2019, 4, 866-867.	4.1	1
332	Onco-Cardiology: tackling the ugly. Herz, 2020, 45, 617-618.	1.1	1
333	High rate of critical coronary stenosis in comatose patients with Non-ST-elevation out-of-hospital cardiac arrest (NSTE-OHCA) undergoing therapeutic hypothermiaâ€"Experience from the HAnnover COoling REgistry (HACORE). PLoS ONE, 2021, 16, e0251178.	2.5	1
334	Risk stratification in cardiogenic shock: from clinical utility to improving outcomes. European Journal of Heart Failure, 2022, 24, 668-671.	7.1	1
335	The year in cardiovascular medicine 2021: heart failure and cardiomyopathies. Cardiologia Croatica, 2022, 17, 27-43.	0.0	1
336	High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy. Clinical Research in Cardiology, 2022, , 1.	3.3	1
337	NO for the Pregnant Mother. Hypertension, 2015, 65, 43-44.	2.7	0
338	Giant pericardial effusion: drain it all?. European Heart Journal, 2016, 37, 2383-2383.	2.2	0
339	The No-Win Resuscitation: Ventricular Septal Rupture and Associated Acute Aortic Occlusion. Case Reports in Critical Care, 2018, 2018, 1-4.	0.4	0
340	Letter by Hilfiker-Kleiner et al Regarding Article, â€œModeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytesâ€• Circulation, 2019, 139, e990-e991.	1.6	0
341	Response to: Antithrombotic therapy for elderly patients with acute coronary syndrome: reasons to be cautious. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 70-70.	3.0	0
342	Cardiomyopathiesâ€"past, present, future. Herz, 2020, 45, 209-211.	1.1	0

#	Article	IF	Citations
343	Klug entscheiden. Kardiologe, 2020, 14, 5-5.	0.0	0
344	What can be learned from the global registry on PPCM?. , 2021, , 83-92.		0
345	Inclusion of oral glucose tolerance testing for diabetes screening in patients with ST-elevation myocardial infarction. European Journal of Preventive Cardiology, 2021, , .	1.8	0
346	What needs to be known about longer-term management and prognosis?. , 2021, , 45-65.		0
347	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. Cardiologia Croatica, 2021, 16, 140-156.	0.0	0
348	Separate Origin of Four Major Coronary Arteries. Cardiovascular Revascularization Medicine, 2021, 25, 86-88.	0.8	0
349	SCORED and SOLOIST: the next scores for SGLT2 inhibitors. Cardiovascular Research, 2021, 117, e49-e51.	3.8	0
350	Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure. Circulation, 2020, 141, 589-591.	1.6	0
351	IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML. Blood, 2020, 136, 32-33.	1.4	0
352	Correspondence. Deutsches Ärzteblatt International, 2022, 119, 57.	0.9	0
353	Coincidence of Spontaneous Coronary Artery Dissection With Apical Takotsubo Syndrome. Circulation Journal, 2022, , .	1.6	0